Fase 1 van PQ912 is in 2011 bekend gemaakt; Fase 2A is bekend gemaakt in 2017, dus Fase 2B valt te verwachten in 2023 en Fase 3 valt te verwachten in 2029........!!!
++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++
Archive: 2011
We are committed to open and transparent communications with the investment community. Probiodrug’s announcements will be made mainly in English.
========================================================================
Probiodrug Announces Top-Line Results of the First Clinical Study of PQ912 for Treatment of Alzheimer’s Disease
Published: 14.11.11
Phase 1 Study of the First Glutaminyl Cyclase (QC) Inhibitor, Which Blocks Formation of Highly Neurotoxic pyroGlu Aß Variants, Shows that PQ912 is Well Tolerated With Therapeutically-Relevant Levels in Blood and Cerebrospinal Fluid HALLE/SAALE, Germany, November 14, 2011 – Probiodrug AG (Probiodrug), a biotech company developing products for the treatment of neurodegenerative and inflammatory diseases, […]
Tagged with: press release , probiodrug
Read more
=========================================================================
Probiodrug and Its Collaborators Will Present Novel Insights into the Pathophysiology of Alzheimer’s Disease at Society for Neuroscience’s Neuroscience 2011 Conference in Washington, D.C.
Published: 09.11.11
Halle/Saale, Germany, November 9, 2011 — Probiodrug AG (Probiodrug), a biotech company developing novel products for the treatment of neurodegenerative and inflammatory diseases with a particular focus on Alzheimer’s disease (AD), today announced that its innovative research on the onset of AD and its consequences for novel treatment options will be endorsed by a series […]
Tagged with: press release , probiodrug
Read more
=========================================================================
Neurodegeneration in Alzheimer’s Disease: The crucial role of QC
Published: 08.09.11
Probiodrug provides further insights into the onset of AD in The Journal of Neuroscience Halle/Saale, September 8th 2011 — Probiodrug AG (Probiodrug), a biotech company developing novel products for the treatment of neurodegenerative and inflammatory disorders, today announced the publication of data providing key insights into the onset and development of Alzheimer?s disease (AD) in […]
Tagged with: press release , probiodrug
Read more
==========================================================================
Neurodegeneration bei Alzheimer-Erkrankung: Schlüsselrolle von QC
Published:
Probiodrug veröffentlicht neue Erkenntnisse zur Entstehung von Alzheimer im Journal of Neuroscience Halle/Saale, 8. September 2011 — Die Probiodrug AG, ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung von neuen Wirkstoffen zur Therapie von entzündlichen und neurodegenerativen Krankheiten fokussiert, hat heute die Veröffentlichung von neuen Daten im Journal of Neuroscience bekannt gegeben. Die Publikation beschreibt […]
Tagged with: press release , probiodrug
Read more
========================================================================
Probiodrug entdeckt grundlegend neues Wirkprinzip zur Behandlung entzündlicher Erkrankungen
Published: 20.07.11
Publikation in EMBO Molecular Medicine erläutert kausale Rolle des Enzyms iso-Glutaminylzyklase (isoQC) Halle/Saale, 20. Juli 2011, 08:00 Uhr MESZ — Die Probiodrug AG, ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung von niedermolekularen Wirkstoffen zur Therapie von entzündlichen und neurodegenerativen Krankheiten fokussiert, hat heute die Publikation von neuen in vivo Daten in der Zeitschrift EMBO […]
Tagged with: press release , probiodrug
Read more
=========================================================================
Probiodrug and its collaborators will present novel insights into the pathophysiology of AD and biomarkers at AD/PD 2011 in Barcelona
Published: 08.03.11
Halle/Saale, March 08th 2011 — Probiodrug AG (Probiodrug), a biotech company developing novel concepts and products for the treatment of neurodegenerative and inflammatory diseases with a particular focus on Alzheimer’s disease (AD), today announced that its innovative research on the onset of AD and its consequences for novel treatment options will be endorsed by a […]
Tagged with: press release , probiodrug
Read more
========================================================================